‘Crazy Monkey’ Poisons Man and Dog: Human and canine seizures due to PB-22, a novel synthetic cannabinoid

Autor:	Roy Gerona, C Li, Derrick Lung, Ben T. Tsutaoka, Kent R. Olson, Hallam Gugelmann
Rok vydání:	2014
Předmět:	Male Indoles Cannabinoids Substance-Related Disorders business.industry medicine.medical_treatment Human patient General Medicine Emergency department Toxicology Young Adult Dogs Seizures Intravenous hydration Anesthesia PB-22 Synthetic cannabinoids Quinolines medicine Animals Humans Dog Diseases Cannabinoid business medicine.drug
Zdroj:	Clinical Toxicology. 52:635-638
ISSN:	1556-9519 1556-3650
DOI:	10.3109/15563650.2014.925562
Popis:	Synthetic cannabinoids have been manufactured, sold, and consumed for recreational purposes since at least 2004; their use has been associated with adverse psychiatric, cardiovascular, renal, pulmonary, and neurologic effects. We report simultaneous canine and human clinical cases associated with exposure to a novel synthetic cannabinoid, PB-22 (QUPIC).A 22-year-old man brought his dog to a veterinary clinic after it had a seizure. During the course of the canine's evaluation, the human patient was witnessed to have a generalized tonic-clonic seizure. He was intubated for agitation and combativeness after his arrival to the emergency department (ED). He was extubated the next day without discernable sequelae. The canine patient received intravenous hydration and was also discharged to home after a period of close observation. The man later endorsed smoking three containers of a substance called "Crazy Monkey" daily for several weeks, but would not disclose how his dog had been exposed. The convulsant effects of "Crazy Monkey" were confirmed in this patient when, three months later, he was sedated, paralyzed, intubated, and admitted to another local hospital for seizures in the context of smoking the same product.Laboratory analysis of samples obtained from the human and canine patients. A sample of the product (labeled "Crazy Monkey") revealed the presence of PB-22 (QUPIC), a novel synthetic cannabinoid. Additionally, serum and urine samples from the human patient contained metabolites of a second compound, UR-144.We present a laboratory-confirmed case report of human and canine neurotoxicity associated with a novel synthetic cannabinoid, PB-22 (QUIPIC).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3db6d40be8f512c456fa6b407f50601 https://doi.org/10.3109/15563650.2014.925562 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.